US20020150921A1
(en)
*
|
1996-02-09 |
2002-10-17 |
Francis Barany |
Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
|
DZ3377A1
(fr)
|
1999-12-24 |
2001-07-05 |
Aventis Pharma Ltd |
Azaindoles
|
YU54202A
(sh)
*
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
US20050009876A1
(en)
*
|
2000-07-31 |
2005-01-13 |
Bhagwat Shripad S. |
Indazole compounds, compositions thereof and methods of treatment therewith
|
US6897231B2
(en)
*
|
2000-07-31 |
2005-05-24 |
Signal Pharmaceuticals, Inc. |
Indazole derivatives as JNK inhibitors and compositions and methods related thereto
|
US7211594B2
(en)
|
2000-07-31 |
2007-05-01 |
Signal Pharmaceuticals, Llc |
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
|
WO2002016348A1
(fr)
*
|
2000-08-09 |
2002-02-28 |
Astrazeneca Ab |
Derives bicycliques antiangiogeniques
|
WO2002022598A1
(fr)
|
2000-09-11 |
2002-03-21 |
Chiron Corporation |
Derives de quinolinone
|
DE10046029A1
(de)
*
|
2000-09-18 |
2002-03-28 |
Bayer Ag |
Indazole
|
EP1380576B1
(fr)
|
2001-04-16 |
2009-11-25 |
Eisai R&D Management Co., Ltd. |
Composes a base de 1h-indazole qui inhibent le jnk
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
US7642278B2
(en)
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
WO2003004488A1
(fr)
*
|
2001-07-03 |
2003-01-16 |
Chiron Corporation |
Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase
|
FR2827861B1
(fr)
*
|
2001-07-27 |
2004-04-02 |
Aventis Pharma Sa |
Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
|
US20040077702A1
(en)
*
|
2001-09-14 |
2004-04-22 |
Wen-Mei Fu |
Treatment of nuerodegenerative diseases
|
KR20040047869A
(ko)
*
|
2001-09-26 |
2004-06-05 |
파마시아 이탈리아 에스.피.에이. |
키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
|
US7271261B2
(en)
*
|
2001-10-19 |
2007-09-18 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazoles and imidazo-[4,5]-pyridines
|
FR2831537B1
(fr)
*
|
2001-10-26 |
2008-02-29 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
|
WO2003035065A1
(fr)
*
|
2001-10-26 |
2003-05-01 |
Aventis Pharmaceuticals Inc |
Benzimidazoles et analogues et leur utilisation comme inhibiteurs de proteines kinases
|
US6897208B2
(en)
|
2001-10-26 |
2005-05-24 |
Aventis Pharmaceuticals Inc. |
Benzimidazoles
|
FR2831536A1
(fr)
*
|
2001-10-26 |
2003-05-02 |
Aventis Pharma Sa |
Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
|
US7074805B2
(en)
*
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
US6867320B2
(en)
*
|
2002-02-21 |
2005-03-15 |
Asahi Kasei Pharma Corporation |
Substituted phenylalkanoic acid derivatives and use thereof
|
WO2003075917A1
(fr)
*
|
2002-03-08 |
2003-09-18 |
Signal Pharmaceuticals, Inc. |
Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
|
FR2836914B1
(fr)
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
US7166293B2
(en)
*
|
2002-03-29 |
2007-01-23 |
Carlsbad Technology, Inc. |
Angiogenesis inhibitors
|
US20050119278A1
(en)
*
|
2002-05-16 |
2005-06-02 |
Che-Ming Teng |
Anti-angiogenesis methods
|
WO2003102151A2
(fr)
*
|
2002-05-30 |
2003-12-11 |
Celgene Corporation |
Procedes d'utilisation d'inhibiteurs de jnk ou de mkk en vue de moduler la differenciation cellulaire et de traiter des troubles myeloproliferatifs et des syndromes myelodysplasiques
|
IL164209A0
(en)
*
|
2002-05-31 |
2005-12-18 |
Eisai Co Ltd |
Pyrazole derivatives and pharmaceutical compositions containing the same
|
JP2004075673A
(ja)
*
|
2002-06-19 |
2004-03-11 |
Mitsubishi Chemicals Corp |
化合物およびこれを用いた有機電界発光素子
|
GB0218625D0
(en)
*
|
2002-08-10 |
2002-09-18 |
Astex Technology Ltd |
Pharmaceutical compounds
|
WO2004014368A1
(fr)
*
|
2002-08-12 |
2004-02-19 |
Sugen, Inc. |
3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
|
US20040087642A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
|
EP1582211A1
(fr)
*
|
2002-12-03 |
2005-10-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de jnk
|
PT1585743E
(pt)
|
2002-12-19 |
2007-07-12 |
Pfizer |
Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
US6933311B2
(en)
*
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
WO2004074283A1
(fr)
*
|
2003-02-21 |
2004-09-02 |
Pfizer Inc. |
Derives d'amino-thiazole substitues par n-heterocyclyle en tant qu'inhibiteurs de la proteine kinase
|
ES2214150B1
(es)
*
|
2003-02-27 |
2005-12-01 |
J. URIACH & CIA S.A. |
"nuevos derivados de pirazolopiridinas".
|
US7468376B2
(en)
|
2003-02-27 |
2008-12-23 |
Palau Pharma, S.A. |
Pyrazolopyridine derivates
|
EP1613313B1
(fr)
|
2003-04-17 |
2007-06-06 |
Janssen Pharmaceutica N.V. |
Derivés de 2-phényl-benzimidazole et de 2-phényl-imidazo- 4,5]-pyridine utilisés comme inhibiteurs de la kinase checkpoint cds1 (chk2) pour le traitement anticancereux
|
FR2854159B1
(fr)
*
|
2003-04-25 |
2008-01-11 |
Aventis Pharma Sa |
Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
|
US7015233B2
(en)
|
2003-06-12 |
2006-03-21 |
Abbott Laboratories |
Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
ITRM20030355A1
(it)
*
|
2003-07-18 |
2005-01-19 |
Sigma Tau Ind Farmaceuti |
Composti ad attivita' citotossica derivati della combretastatina.
|
AU2004261459B2
(en)
|
2003-07-22 |
2008-06-26 |
Astex Therapeutics Limited |
3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
CA2518951A1
(fr)
*
|
2003-07-30 |
2005-02-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibiteur de la proteine kinase
|
US7008953B2
(en)
|
2003-07-30 |
2006-03-07 |
Agouron Pharmaceuticals, Inc. |
3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
KR20060119705A
(ko)
*
|
2003-07-30 |
2006-11-24 |
교와 핫꼬 고교 가부시끼가이샤 |
인다졸 유도체
|
US20050090529A1
(en)
*
|
2003-07-31 |
2005-04-28 |
Pfizer Inc |
3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
|
BRPI0413234A
(pt)
*
|
2003-08-01 |
2006-10-03 |
Genelabs Tech Inc |
derivados de imidazola bicìclica contra flaviviridae
|
US20050113576A1
(en)
*
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
WO2005014554A1
(fr)
*
|
2003-08-08 |
2005-02-17 |
Astex Therapeutics Limited |
Composes 1h-indazole-3-carboxamide utilises comme modulateurs de la mapkap kinase
|
AU2004265191A1
(en)
|
2003-08-14 |
2005-02-24 |
Asahi Kasei Pharma Corporation |
Substituted arylalkanoic acid derivative and use thereof
|
JP2005089457A
(ja)
|
2003-09-03 |
2005-04-07 |
Yung Shin Pharmaceutical Industry Co Ltd |
骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
|
US6984652B2
(en)
*
|
2003-09-05 |
2006-01-10 |
Warner-Lambert Company Llc |
Gyrase inhibitors
|
RU2358978C2
(ru)
*
|
2003-09-08 |
2009-06-20 |
Авентис Фармасьютикалз Инк. |
Тиенопиразолы
|
JP4110324B2
(ja)
*
|
2003-10-15 |
2008-07-02 |
宇部興産株式会社 |
新規インダゾール誘導体
|
ZA200603719B
(en)
*
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
|
EA012621B1
(ru)
|
2003-11-07 |
2009-10-30 |
Чирон Корпорейшн |
Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
|
US20060179711A1
(en)
*
|
2003-11-17 |
2006-08-17 |
Aerogrow International, Inc. |
Devices and methods for growing plants
|
CA2546493A1
(fr)
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc |
Composes d'indazole et leurs procedes d'utilisation en tant qu'inhibiteurs de la proteine kinase
|
US7488817B2
(en)
*
|
2004-02-02 |
2009-02-10 |
The Trustees Of The University Of Pennsylvania |
Metal complex protein kinase inhibitors
|
WO2005094830A1
(fr)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinaisons d'inhibiteurs de transduction de signaux
|
WO2005094823A1
(fr)
*
|
2004-03-30 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
INHIBITEUR DE Flt-3
|
GB0409080D0
(en)
*
|
2004-04-23 |
2004-05-26 |
Biofocus Discovery Ltd |
Compounds which interact with protein kinases
|
AU2005266494B2
(en)
*
|
2004-07-27 |
2009-09-10 |
Novartis Ag |
Inhibitors of Hsp90
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
FR2876584B1
(fr)
*
|
2004-10-15 |
2007-04-13 |
Centre Nat Rech Scient Cnrse |
Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
|
WO2006054143A1
(fr)
*
|
2004-11-17 |
2006-05-26 |
Pfizer Inc. |
Formes polymorphes de {5-[3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
|
US20060116519A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Agouron Pharmaceuticals, Inc. |
Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
|
WO2006058007A2
(fr)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
|
AU2005321091B2
(en)
|
2004-12-30 |
2012-04-12 |
Astex Therapeutics Limited |
Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
|
BRPI0606480A
(pt)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
AU2006207325B2
(en)
|
2005-01-21 |
2012-08-16 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
AU2006209712B2
(en)
|
2005-01-27 |
2011-06-09 |
Kyowa Hakko Kirin Co., Ltd. |
IGF-1R inhibitor
|
GT200600042A
(es)
|
2005-02-10 |
2006-09-27 |
Aventis Pharma Inc |
Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
|
US20070004777A1
(en)
*
|
2005-03-23 |
2007-01-04 |
Bhagwat Shripad S |
Methods for treating or preventing acute myelogenous leukemia
|
US8093244B2
(en)
|
2005-03-29 |
2012-01-10 |
Icos Corporation |
Heteroaryl urea derivatives useful for inhibiting CHK1
|
ZA200709240B
(en)
*
|
2005-04-29 |
2009-06-24 |
Celgene Corp |
Solid forms of 1-(5-(IH-1,2,4-triazol-5-yl)(IH-indazol-3-yl)-3-(2-piperidylethoxy)benzene
|
PT1888556E
(pt)
|
2005-05-17 |
2012-02-03 |
Novartis Ag |
Métodos para sintetizar compostos heterocíclicos
|
US7541367B2
(en)
|
2005-05-31 |
2009-06-02 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
ES2580108T3
(es)
|
2005-07-11 |
2016-08-19 |
Aerie Pharmaceuticals, Inc |
Compuestos de isoquinolina
|
WO2007058626A1
(fr)
*
|
2005-11-16 |
2007-05-24 |
S*Bio Pte Ltd |
Composes d'indazole
|
CA2627544C
(fr)
|
2005-11-29 |
2015-07-07 |
Novartis Ag |
Formulations de quinolinones pour le traitement du cancer
|
KR20070077468A
(ko)
*
|
2006-01-23 |
2007-07-26 |
크리스탈지노믹스(주) |
단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물
|
EP1986643A1
(fr)
*
|
2006-02-10 |
2008-11-05 |
Summit Corporation Plc |
Traitement de la dystrophie musculaire de duchenne
|
US20090291968A1
(en)
*
|
2006-03-23 |
2009-11-26 |
Guy Georges |
Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
|
CN101484426A
(zh)
|
2006-06-30 |
2009-07-15 |
协和发酵麒麟株式会社 |
Aurora抑制剂
|
EP2036893A4
(fr)
|
2006-06-30 |
2011-04-13 |
Kyowa Hakko Kirin Co Ltd |
INHIBITEUR DE KINASE Abl
|
WO2008020606A1
(fr)
*
|
2006-08-16 |
2008-02-21 |
Kyowa Hakko Kirin Co., Ltd. |
Agent anti-angiogénique
|
MX2009002018A
(es)
*
|
2006-08-25 |
2009-03-05 |
Abbott Lab |
Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos.
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
WO2008036540A2
(fr)
|
2006-09-20 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Inhibiteurs de la rho-kinase
|
WO2008044045A1
(fr)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
WO2008044041A1
(fr)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
US8071779B2
(en)
*
|
2006-12-18 |
2011-12-06 |
Inspire Pharmaceuticals, Inc. |
Cytoskeletal active rho kinase inhibitor compounds, composition and use
|
US20100022517A1
(en)
*
|
2006-12-18 |
2010-01-28 |
Richards Lori A |
Ophthalmic formulation of rho kinase inhibitor compound
|
EP2450346A1
(fr)
|
2006-12-20 |
2012-05-09 |
Abbott Laboratories |
Antagonistes du récepteur TRPV1 et utilisations associées
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
WO2008106594A2
(fr)
*
|
2007-02-28 |
2008-09-04 |
The Arizona Board Of Regents, On Behalf Of The University Of Arizona |
Inhibiteurs de la nucléophosmine (npm) et procédés d'induction de l'apoptose
|
US20100104567A1
(en)
|
2007-03-05 |
2010-04-29 |
Kyowa Hakko Kirin Co., Ltd. |
Pharmaceutical composition
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
AU2008262038A1
(en)
*
|
2007-06-08 |
2008-12-18 |
AbbVie Deutschland GmbH & Co. KG |
5-heteroaryl substituted indazoles as kinase inhibitors
|
JP5348725B2
(ja)
*
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
US8455514B2
(en)
|
2008-01-17 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-and 7-amino isoquinoline compounds and methods for making and using the same
|
EP2489660A1
(fr)
*
|
2008-03-20 |
2012-08-22 |
Abbott Laboratories |
Procédés de fabrication d'agents de système nerveux central qui sont des antagonistes TRPV1
|
JP5198560B2
(ja)
|
2008-04-28 |
2013-05-15 |
旭化成ファーマ株式会社 |
フェニルプロピオン酸誘導体及びその用途
|
US8106039B2
(en)
*
|
2008-04-30 |
2012-01-31 |
The Trustees Of The University Of Pennsylvania |
Metal complex phosphatidyl-inositol-3-kinase inhibitors
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
EP2417127B1
(fr)
|
2009-04-06 |
2014-02-26 |
University Health Network |
Inhibiteurs de kinases et procédé de traitement du cancer avec ceux-ci
|
JP2012525386A
(ja)
*
|
2009-05-01 |
2012-10-22 |
アエリエ・ファーマシューティカルズ・インコーポレーテッド |
疾患の治療のための二重機構阻害剤
|
CA2770320A1
(fr)
*
|
2009-08-10 |
2011-02-17 |
Epitherix, Llc |
Indazoles utiles comme inhibiteurs de la voie de signalisation de wnt/beta-catenine et utilisations therapeutiques de ceux-ci
|
US8252812B2
(en)
|
2009-08-10 |
2012-08-28 |
Samumed, Llc |
Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof
|
UY33001A
(es)
|
2009-11-06 |
2011-05-31 |
Boehringer Ingelheim Int |
Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
|
JP5822844B2
(ja)
*
|
2009-12-21 |
2015-11-24 |
サミュメッド リミテッド ライアビリティ カンパニー |
1H−ピラゾロ[3,4−b]ピリジンおよびその治療的使用
|
WO2011123947A1
(fr)
|
2010-04-06 |
2011-10-13 |
University Health Network |
Synthèse de 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2'-ones chirales
|
WO2012020725A1
(fr)
*
|
2010-08-10 |
2012-02-16 |
塩野義製薬株式会社 |
Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
|
HUE054810T2
(hu)
|
2010-08-18 |
2021-09-28 |
Biosplice Therapeutics Inc |
Diketonok és hidroxiketonok mint katenin-jelzõút aktivátorok
|
TWI537258B
(zh)
|
2010-11-05 |
2016-06-11 |
百靈佳殷格翰國際股份有限公司 |
六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物
|
WO2012078777A1
(fr)
*
|
2010-12-09 |
2012-06-14 |
Amgen Inc. |
Composés bicycliques en tant qu'inhibiteurs de pim
|
EP2688886A1
(fr)
|
2011-03-22 |
2014-01-29 |
Amgen Inc. |
Composés d'azole utilisés en tant qu'inhibiteurs des pim
|
WO2012135799A1
(fr)
*
|
2011-04-01 |
2012-10-04 |
University Of Utah Research Foundation |
Analogues de 3-(1h-benzo[d]imidazol-2-yl)-1h-indazole substitués en tant qu'inhibiteurs de la pdk1 kinase
|
EP3473099A1
(fr)
|
2011-09-14 |
2019-04-24 |
Samumed, LLC |
Indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation par wnt/b-caténine
|
WO2013063321A1
(fr)
|
2011-10-25 |
2013-05-02 |
The General Hospital Corporation |
Inhibiteurs de la voie wnt/b-caténine et leurs procédés d'utilisation
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
AU2013256141B2
(en)
|
2012-05-04 |
2016-05-12 |
Samumed, Llc |
1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2014041518A1
(fr)
*
|
2012-09-14 |
2014-03-20 |
Glenmark Pharmaceuticals S.A. |
Composés thiénopyrrole comme inhibiteurs de l'itk
|
CA2897400A1
(fr)
*
|
2013-01-08 |
2014-07-17 |
Samumed, Llc |
Inhibiteurs de 3-(benzoimidazol-2-yl)-indazole de la voie de signalisation par wnt et leurs utilisations therapeutiques
|
CN104370889A
(zh)
*
|
2013-01-24 |
2015-02-25 |
韩冰 |
一类降低眼压的化合物及其制备方法和用途
|
AU2014218720B2
(en)
|
2013-02-22 |
2018-09-27 |
Samumed, Llc |
Gamma-diketones as Wnt/beta -catenin signaling pathway activators
|
WO2014134774A1
(fr)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
EP2964221B1
(fr)
|
2013-03-04 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine
|
WO2014134776A1
(fr)
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
WO2014134772A1
(fr)
*
|
2013-03-04 |
2014-09-12 |
Merck Sharp & Dohme Corp. |
Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
|
PT3811943T
(pt)
|
2013-03-15 |
2023-03-15 |
Aerie Pharmaceuticals Inc |
Composto para uso no tratamento de distúrbios oculares
|
WO2015015519A1
(fr)
|
2013-07-31 |
2015-02-05 |
Council Of Scientific & Industrial Research |
Nouveaux composés d'indazole et leur procede de preparation
|
KR102195494B1
(ko)
|
2013-10-18 |
2020-12-28 |
유니버시티 헬스 네트워크 |
췌장암 치료
|
CN106687454B8
(zh)
|
2014-07-24 |
2019-08-30 |
贝达医药公司 |
作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
|
AU2015305373B2
(en)
|
2014-08-20 |
2020-12-10 |
Samumed, Llc |
Gamma-diketones for treatment and prevention of aging skin and wrinkles
|
WO2016040182A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
|
WO2016040193A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
WO2016040188A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040185A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
|
WO2016040181A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040190A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
|
WO2016040184A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
WO2016040180A1
(fr)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
|
GB201506658D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
GB201506660D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
GB201511382D0
(en)
|
2015-06-29 |
2015-08-12 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
WO2017024010A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
|
WO2017023986A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
|
WO2017024021A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023989A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
WO2017023984A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leurs utilisations thérapeutiques
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023996A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
|
WO2017023993A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024025A1
(fr)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023975A1
(fr)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines et leus utilisations thérapeutiques
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
JP6898306B2
(ja)
*
|
2015-08-07 |
2021-07-07 |
ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド |
Fgfr及びvegfr阻害剤であるビニル化合物
|
CA3004506A1
(fr)
|
2015-11-06 |
2017-05-11 |
Samumed, Llc |
Utilisation de n-(5-(3-(7-(3- fluorophenyle)-3h-imidazo[4,5-c]pyridine-2-yl)-1h-indazol-5-yl)pyridine-3-yl)-3-methylbutanamide dans le traitement de l'arthrose
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
JP6832946B2
(ja)
|
2015-11-17 |
2021-02-24 |
アエリエ ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤およびその中間体の調製方法
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
AR108326A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
CA3026076A1
(fr)
|
2016-06-01 |
2017-12-07 |
Samumed, Llc |
Procede de preparation de n-(5-(3-(7-(3-fluorophenyl))-3 h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
US11078192B2
(en)
|
2016-07-05 |
2021-08-03 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
|
WO2018013430A2
(fr)
|
2016-07-12 |
2018-01-18 |
Arisan Therapeutics Inc. |
Composés hétérocycliques pour le traitement d'une infection à arenavirus
|
KR102568079B1
(ko)
|
2016-08-31 |
2023-08-17 |
에어리 파마슈티컬즈, 인코포레이티드 |
안과용 조성물
|
WO2018075858A1
(fr)
|
2016-10-21 |
2018-04-26 |
Samumed, Llc |
PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
|
JP2019533702A
(ja)
|
2016-11-07 |
2019-11-21 |
サミュメッド リミテッド ライアビリティ カンパニー |
単回用量の調整済み注射用製剤
|
MX2019011784A
(es)
|
2017-03-31 |
2019-11-18 |
Aerie Pharmaceuticals Inc |
Compuestos de aril ciclopropil-amino-isoquinolinil amida.
|
US10604514B2
(en)
|
2017-10-19 |
2020-03-31 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
|
US10413537B2
(en)
|
2017-10-27 |
2019-09-17 |
Samumed, Llc |
6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
|
WO2019084497A1
(fr)
|
2017-10-27 |
2019-05-02 |
Samumed, Llc |
6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
|
WO2019089835A1
(fr)
|
2017-10-31 |
2019-05-09 |
Samumed, Llc |
Diazanaphthalèn-3-yl carboxamides, préparation et utilisation de ceux-ci
|
US11384048B2
(en)
|
2017-12-29 |
2022-07-12 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd. |
Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
|
CA3091913A1
(fr)
|
2018-02-23 |
2019-08-29 |
Samumed, Llc |
Indazole-3-carboxamides substitues par heteroaryle en position 5, preparation et utilisation associees
|
WO2019241540A1
(fr)
|
2018-06-15 |
2019-12-19 |
Samumed, Llc |
Macrocycles contenant de l'indazole et utilisations thérapeutiques associées
|
AU2019337703B2
(en)
|
2018-09-14 |
2023-02-02 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
WO2020150545A1
(fr)
|
2019-01-17 |
2020-07-23 |
Samumed, Llc |
DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
|
EP4056558A4
(fr)
*
|
2019-11-06 |
2023-12-27 |
Jinan University |
Composé d'indazole, composition pharmaceutique de celui-ci et ses applications
|
WO2021125229A1
(fr)
*
|
2019-12-17 |
2021-06-24 |
富士フイルム株式会社 |
Composé d'indazole ou sel de celui-ci, et composition pharmaceutique
|
WO2021121420A1
(fr)
*
|
2019-12-20 |
2021-06-24 |
江苏凯迪恩医药科技有限公司 |
Composé benzopyrazole et intermédiaire, procédé de préparation correspondant et utilisation associée
|
WO2021168341A1
(fr)
|
2020-02-21 |
2021-08-26 |
Samumed, Llc |
Formes solides de 1-(5-(3-(7-(3-fluorophényl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-diméthylméthanamine
|
CN112724134B
(zh)
*
|
2021-01-14 |
2022-04-01 |
复旦大学 |
氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用
|
WO2023240138A1
(fr)
*
|
2022-06-08 |
2023-12-14 |
Blossomhill Therapeutics, Inc. |
Macrocycles contenant de l'indazole et leur utilisation
|